Navigation Links
InNexus Biotechnology Announces New Patents Protecting Novel Cell Penetrating DXL(TM) Antibodies
Date:3/6/2009

- Company Receives Allowance of Patent Claims in the U.S. and in India -

- InNexus Biotechnology CEO Highlighted in Nature Biotechnology -

BRITISH COLUMBIA, Canada, March 6 /PRNewswire-FirstCall/ -- InNexus Biotechnology Inc. (OTC Bulletin Board: IXSBF; TSX VENTURE: IXS; http://www.ixsbio.com), a drug development company commercializing the next generation of monoclonal antibodies based on its Dynamic Cross Linking (DXL(TM)) technology, announces that it has received a notice of allowance on patent claims in the United States (Serial No. 11/119,404) and a patent grant in India (National Phase Application No. 2424/CHENP/2005) further expanding its protection of InNexus' DXL(TM) technology.

Speaking on today's announcement, InNexus Chairman and CEO, Jeff Morhet said, "DXL(TM) antibodies that penetrate directly into cells, is an exciting achievement for InNexus and our industry. As we've continued to expand our patent portfolio and discover new technologies to develop products, the team has aggressively pursued patent protection for our novel inventions. Patents are the currency of our industry and a driver for enhanced value for our shareholders and potential use of these cell penetrating DXL(TM) antibodies represents another frontier for the use of antibodies for therapeutic and diagnostic applications."

Dr. Thomas Kindt, Chief Scientific Officer of InNexus said, "The claims in these patents are directed toward the addition of membrane transport sequences to DXL antibodies, which facilitate penetration of DXL(TM) antibodies into cancer cells. The ability to direct our DXL(TM) antibodies to intracellular targets by the addition of a membrane transport sequence, imparts great therapeutic potential in a number of applications. The patents and applications also include coverage for new molecules and products of InNexus. We like to say We Build
'/>"/>

SOURCE InNexus Biotechnology Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. FDA Provides A Positive Review of InNexus Biotechnology Development Plan for Lead Product
2. InNexus Completes Previously Announced Private Placement
3. InNexus Biotechnology Announces New EGFR Antibody DXL1218 Targeting Colorectal Cancer and Announces $1.25 Million Private Placement
4. InNexus Biotechnology Receives Patent Grants in Europe
5. InNexus Biotechnology CEO to Present at the 7th Annual BIO Investor Forum
6. InNexus Biotechnology CEO to Present at BioContactQuebec 2008
7. St. Josephs Hospital and InNexus Biotechnology Enter Collaborative Partnership
8. InNexus Biotechnology Strengthens Patent Team With New Leadership
9. InNexus Biotechnology CEO to Present at The Wall Street Analyst Forum in NYC
10. InNexus Biotechnology Announces Launch of Large Scale Primate Study of DXL625
11. InNexus Biotechnology CEO and Chief Scientific Officer to Present at IBCs Annual World Congress Conference in Boston on Aug 6th
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/30/2014)... 2014 The Global and China ... in-depth study on the current state of the ... , The report provides a basic overview of ... structure. Global market analysis and Chinese domestic market ... developments, trends and competitive landscape of the market. ...
(Date:8/29/2014)... 2014  Pfenex Inc. (NYSE MKT: PFNX), a ... high-value and difficult to manufacture proteins including biosimilar ... financial results for the second quarter ended June ... of our initial public offering, we have the ... candidates, derived from our proprietary protein expression platform," ...
(Date:8/29/2014)... one of the most promising technologies for future quantum ... (photons) instead of electrons. First, it is necessary to ... and control their direction. Researchers around the world have ... but now scientists at the Niels Bohr Institute have ... one at a time and in a particular direction. ...
(Date:8/29/2014)... New York (PRWEB) August 29, 2014 ... valued at $5.6 billion in 2019. It is ... from 2013 to 2019, and was valued at ... report published by Transparency Market Research. , For ... visit: http://www.transparencymarketresearch.com/companion-diagnostics-market.html . , The research report, ...
Breaking Biology Technology:Electrical Insulating Varnish Market World, China Regional Analysis & 2020 Forecasts Available at DeepResearchReports.com 2Electrical Insulating Varnish Market World, China Regional Analysis & 2020 Forecasts Available at DeepResearchReports.com 3Pfenex Reports Second Quarter 2014 Results and Provides Business Update 2Pfenex Reports Second Quarter 2014 Results and Provides Business Update 3Pfenex Reports Second Quarter 2014 Results and Provides Business Update 4Pfenex Reports Second Quarter 2014 Results and Provides Business Update 5Pfenex Reports Second Quarter 2014 Results and Provides Business Update 6Pfenex Reports Second Quarter 2014 Results and Provides Business Update 7Pfenex Reports Second Quarter 2014 Results and Provides Business Update 8Breakthrough in light sources for new quantum technology 2Companion Diagnostics Market to Hit $5.6 Billion in 2019: Transparency Market Research 2Companion Diagnostics Market to Hit $5.6 Billion in 2019: Transparency Market Research 3
... Neogen Corporation,(Nasdaq: NEOG ) announced today that ... which ended Nov. 30, increased 34% from the previous ... income in the,quarter rose to $0.22 per share, compared ... of $3,254,000 set another quarterly,record for the 25-year-old company., ...
... 3 /PRNewswire/-- Intercept Pharmaceuticals, Inc., a,clinical-stage biopharmaceutical ... fibrotic and metabolic diseases, today announced the,appointment ... created position of,Chief Scientific Officer. Dr. Adorini ... research and development, recently serving as Chief ...
... Chimerix, Inc., a,biotechnology company developing orally available ... FRCA, FFPM has joined the,company as Chief Medical ... served as the Chief Medical,Officer and Chief Operating ... was responsible for the design of clinical drug,development ...
Cached Biology Technology:Neogen Reports 34% Increase in Net Income, 23% Increase in Revenues 2Neogen Reports 34% Increase in Net Income, 23% Increase in Revenues 3Neogen Reports 34% Increase in Net Income, 23% Increase in Revenues 4Neogen Reports 34% Increase in Net Income, 23% Increase in Revenues 5Intercept Pharmaceuticals Names Dr. Luciano Adorini Chief Scientific Officer 2Chimerix Appoints Neil Frazer, M.B., Ch.B., FRCA, FFPM as Chief Medical Officer 2
(Date:8/29/2014)... at UC Davis have made some surprising discoveries ... Studying simian immunodeficiency virus (SIV), the team found ... cells are early responders to viral invasion and ... a cytokine called interleukin-1 beta (IL-1β). , ... causes breakdown of the gut epithelium that provides ...
(Date:8/29/2014)... Scientists at the Barshop Institute for Longevity and Aging ... UT Health Science Center at San Antonio, have found ... longest-lived rodent, the naked mole rat. , They ... mole rats protects and alters the activity of the ... , The factor also protects proteasome function in human, ...
(Date:8/29/2014)... recently, little has been known about what genetic changes ... of scientists, one of whom is a University of ... that genes controlling the development of the brain and ... The study was published Aug. 28 in Science ... is online at http://www.sciencemag.org/ ., The domestication of ...
Breaking Biology News(10 mins):The early cost of HIV 2Factor in naked mole rat's cells enhances protein integrity 2New research reveals how wild rabbits were genetically transformed into tame rabbits 2New research reveals how wild rabbits were genetically transformed into tame rabbits 3
... November 15, 2013 Millions of families in the ... to insufficient money or other resources. To combat food ... upon the Supplemental Nutrition Assistance Program (SNAP), the largest ... In the past, SNAP has been shown to reduce ...
... , Nov. 14, 2013  Shareholder rights law firm Robbins Arroyo ... (NASDAQ: VICL ) has filed a federal securities ... the Southern District of California.  The complaint alleges that the ... Exchange Act of 1934 between February, 8, 2012 and August ...
... (Nov. 14, 2013) -- A low-cost device that Rice ... more easily will be rolled out to teaching hospitals ... from pharmaceutical giant GlaxoSmithKline (GSK) and London-based charity Save ... CPAP," earned the top prize in GSK and Save ...
Cached Biology News:Enrollment in SNAP does not substantially improve food security or dietary quality 2Attention Vical Incorporated Investors: Vical Misled Investors According to a Newly Filed Class Action 2Prize will expand use of life-saving neonatal device in Africa 2Prize will expand use of life-saving neonatal device in Africa 3